ArticleOphthalmology science2026
Influence of Social Determinants of Health on Presenting Visual Acuity in Retinal Vein Occlusions.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To describe the impact of social determinants of health (SDOH) on visual acuity (VA) at presentation among patients with retinal vein occlusion (RVO). Design: A retrospective single-center cohort study. Subjects: All patients with RVO (central and branch retinal vein occlusion [CRVO and BRVO]) who received their first intravitreal anti-VEGF injection between January 2015 and March 2025 at a single center. Methods: Sociodemographic factors including age, gender, race, and ethnicity were recorded. Social deprivation index (SDI) scores, a proxy for SDOH were determined using zip codes. An aggregate SDOH score was calculated and divided into quintiles, with quintile 5 (Q5) representing the highest SDOH burden. Information on hypertension and smoking status were also collected. Data on best available VA at presentation measurements were collected and were categorized as mild (20/40 or better), moderate (20/50 to 20/100), and severe vision loss (20/200 or worse). Main Outcome Measures: Factors affecting degree of vision loss at presentation. Results: A total of 9698 patients with RVO were included. Of these, 57% (n = 5490/9698) had a BRVO, and 43% (n = 4208/9698) had a CRVO. The proportion of patients with mild, moderate, and severe vision loss was 25% (n = 2425/9698), 41.8% (n = 4049/9698), and 33.1% (n = 3206/9698), respectively. On multivariable analysis, increasing SDI quintiles (higher SDOH burden) were associated with worse presenting baseline VA in patients with RVO (odds ratio [OR] 1.32, 95% confidence interval [CI]: 1.13-1.54; Conclusions: Our study reveals associations between adverse SDOH and presenting VA among patients with RVO. Evaluating and intervening on effects of adverse SDOH may be a means to improve outcomes of patients with RVO. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.